Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STI-571 and Chemotherapy in Lymphoid Blast Crisis CML and Ph+ ALL
NCT00015860Phase 2Completed
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- May 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of imatinib in chronic myeloid leukemia (CML) and Acute lymphoblastic leukemia, Philadelphia chromosome positive, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Maximum Tolerated Dose of Daunorubicin. Started May 2001; status: completed.
02
Drugs
03
Conditions
chronic myeloid leukemia (CML)Acute lymphoblastic leukemia, Philadelphia chromosome positive
Beyond the preview
Go deeper on NCT00015860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00015860.